Shares of GH Research (NASDAQ:GHRS) rose roughly 12% in premarket trading Thursday after market reports suggested that Eli Lilly is engaged in talks to acquire Atai Life Sciences (NASDAQ:ATAI). Atai shares reacted strongly to the news, climbing as much as 53% in premarket trading.
Market commentary from RBC Capital Markets helped frame the move. Analyst Brian Abrahams said the psychedelic sector is likely to sustain upward momentum in response to the reports. Abrahams specifically identified GH Research as the "most direct and compelling read-through, given the near-identical mechanism and target indication of its lead asset, GH001, to ATAI’s BPL-003."
The reported potential acquisition by pharmaceutical company Eli Lilly (NYSE:LLY) represents a notable development in the psychedelic drug segment, where multiple companies are pursuing treatments for mental health conditions. While coverage and commentary have focused on the possible deal, market pricing shows investors rapidly repricing exposure to companies with similar clinical approaches.
RBC's analysis highlights the scientific similarities between GH Research's lead therapy and Atai's BPL-003. According to the analyst's assessment, GH001 and BPL-003 share a comparable mechanism of action and are aimed at the same clinical indication, which helps explain why GH Research's stock moved in parallel with Atai's on the news.
Investors reacted quickly to the reports, with Atai registering a premarket surge of about 53% and GH Research trading up approximately 12% ahead of the opening bell. The commentary cited in market coverage linked the sectorwide interest to the possibility of a strategic transaction involving a major pharmaceutical firm.
At the same time, the reporting indicates that the conversation around consolidation in the psychedelic drug space is drawing attention from market participants and analysts. That attention has translated into notable price volatility for companies with assets described as mechanistically similar to Atai's lead program.
As the situation develops, market participants and observers will be watching for confirmation of any transaction and for further analyst commentary assessing read-throughs to other companies with comparable clinical assets. For now, the price moves reflect markets responding to reports and analyst interpretation of how closely peer programs align with Atai's lead candidate.